On Octobre 24, 2016, Melinta Therapeutics announced its submit a NDA for approval of IV Baxdela for treatment of patients with acute bacterial skin and skin structure infections.
On October 24, 2016, Melinta Therapeutics announced it submitted a NDA for approval of IV Baxdela for the treatment of patients with acute bacterial skin and skin structure infections.